Celera Genomics, Inpharmatica in Discovery Pact

Author:
Publish date:

Celera Genomics

(CRA)

entered an agreement with Inpharmatica to commercialize a new platform for finding and developing drugs.

The product will combine Inpharmatica's protein structure and function prediction technology with Celera's gene sequence products in a system to be known as Celera Edition Biopendium.

The companies said they will co-market the platform and expect to launch it early next year.